Article Information
History
- April 17, 2021.
Article Versions
- Version 1 (April 7, 2021 - 09:31).
- You are currently viewing Version 2 of this article (April 17, 2021 - 09:37).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- David E. Gard1,*,
- Mollie M. Pleet2,3,
- Ellen R. Bradley2,3,
- Andrew Penn2,
- Matthew L. Gallenstein1,
- Lauren S. Riley1,
- Meghan DellaCrosse4,
- Emily Garfinkle5,
- Erin E. Michalak6 and
- Joshua D. Woolley2,3
- 1San Francisco State University, San Francisco, CA USA
- 2University of California San Francisco, San Francisco, CA USA
- 3San Francisco Veteran’s Affairs Medical Center, San Francisco, CA USA
- 4The Wright Institute, Berkeley, CA USA
- 5Palo Alto University-Pacific Graduate School of Psychology, Palo Alto, CA USA
- 6University of British Columbia, Vancouver, BC Canada
- ↵*Corresponding author:
David E. Gard, Ph.D., Department of Psychology, San Francisco State University, 1600 Holloway Ave, San Francisco, California 94132 USA, dgard{at}sfsu.edu
Posted April 17, 2021.
Evaluating the Risk of Psilocybin for the Treatment of Bipolar Depression: A Review of the Research Literature and Published Case Studies
